113 related articles for article (PubMed ID: 15806568)
1. Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.
Dubow J; Kim A; Leikin J; Cumpston K; Bryant S; Rezak M
Mov Disord; 2005 Jul; 20(7):877-80. PubMed ID: 15806568
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin-B and the management of hyperhidrosis.
Baumann LS; Halem ML
Clin Dermatol; 2004; 22(1):60-5. PubMed ID: 15158547
[TBL] [Abstract][Full Text] [Related]
3. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
Cardoso F
Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
[TBL] [Abstract][Full Text] [Related]
4. Expanding use of botulinum toxin.
Bhidayasiri R; Truong DD
J Neurol Sci; 2005 Aug; 235(1-2):1-9. PubMed ID: 15990116
[TBL] [Abstract][Full Text] [Related]
5. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
[TBL] [Abstract][Full Text] [Related]
7. Clinical failure of botulinum toxin A in movement disorders.
Savica R; Grossardt BR; Bower JH; Klassen BT; Matsumoto JY
Parkinsonism Relat Disord; 2012 Jan; 18(1):73-5. PubMed ID: 21880538
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
[TBL] [Abstract][Full Text] [Related]
9. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
Greene PE; Fahn S
Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Wan XH; Vuong KD; Jankovic J
Chin Med Sci J; 2005 Mar; 20(1):44-7. PubMed ID: 15844312
[TBL] [Abstract][Full Text] [Related]
11. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.
Tintner R; Gross R; Winzer UF; Smalky KA; Jankovic J
Neurology; 2005 Sep; 65(5):765-7. PubMed ID: 16157918
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin B treatment in children with spastic movement disorders: a pilot study.
Schwerin A; Berweck S; Fietzek UM; Heinen F
Pediatr Neurol; 2004 Aug; 31(2):109-13. PubMed ID: 15301829
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
Lew MF; Brashear A; Factor S
Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin in movement disorders.
Jankovic J
Curr Opin Neurol; 1994 Aug; 7(4):358-66. PubMed ID: 7952246
[TBL] [Abstract][Full Text] [Related]
15. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
Sankhla C; Jankovic J; Duane D
Mov Disord; 1998 Jan; 13(1):150-4. PubMed ID: 9452341
[TBL] [Abstract][Full Text] [Related]
16. Comparison of botulinum toxins A and B in the aesthetic treatment of facial rhytides.
Sadick NS; Herman AR
Dermatol Surg; 2003 Apr; 29(4):340-7. PubMed ID: 12656810
[TBL] [Abstract][Full Text] [Related]
17. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
Dressler D; Benecke R
Eur Neurol; 2003; 49(1):34-8. PubMed ID: 12464716
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of movement disorders using botulinum toxin].
Burgunder JM
Schweiz Med Wochenschr; 1992 Sep; 122(36):1311-6. PubMed ID: 1411387
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
Carruthers A; Carruthers J; Flynn TC; Leong MS
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S60-8. PubMed ID: 17241416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
